ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1412	National Cancer Institute	Html	en	Lung Cancer Prevention (PDQ®)–Patient Version	Expert-reviewed information summary about factors that may influence the risk of developing lung cancer and about research aimed at the prevention of this disease.	skin cancer 0.349544 cancer treatment 0.344722 cancer prevention trials 0.366779 lung cancer screening 0.424963 lung cancer prevention 0.444623 prevention clinical trials 0.358195 protective factors 0.365293 following PDQ summaries 0.35677 PDQ cancer information 0.428189 lung cancer 0.930545 clinical trials 0.420475 secondhand smoke 0.364049 important risk factor 0.350351 cancer information summary 0.398033 small cell lung 0.428578 left lung 0.393411 breast cancer prevention 0.35675 cancer patients 0.344267 cancer risk factor 0.388012 low-dose spiral ct 0.356728 NCI PDQ cancer 0.3773 radiation therapy 0.36772 new cases 0.35557 CT scans 0.355102	cancer risk factors 0.383293 cancer protective factor 0.369464 smokers 0.342644 Atomic bomb radiation 0.359839 Cancer Information Service 0.361682 spiral CT scans 0.353441 common cancer 0.34956 smoking 0.374366 Prevention Editorial Board 0.360434 lower their risk 0.346462 National Cancer Institute 0.402346 new lung cancers 0.398324 smoking low tar 0.343862 Cancer Care page 0.356844 right lung 0.388076 non-small cell lung 0.429832 people 0.358421 PDQ summary 0.34571 cancer -causing agents 0.363798 cancer clinical trials 0.36639 cell lung cancer 0.479294 risk factors 0.409463 cancer information summaries 0.364825 comprehensive cancer information 0.364576	CLICK HERE
1520	National Cancer Institute	Html	null	Esophageal Cancer Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of esophageal cancer.			CLICK HERE
1527	National Cancer Institute	Html	en	Ovarian Germ Cell Tumors Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of ovarian germ cell tumors.	cancer treatment 0.301769 cancer spreads 0.255348 malignant tumor cells 0.277558 body 0.299082 germ cell tumor 0.800721 chemotherapy 0.280839 PDQ cancer information 0.300273 Recurrent ovarian germ 0.277404 clinical trial search 0.309632 clinical trials 0.590656 cancer information summary 0.281932 clinical trial 0.395991 ovarian cancer 0.264692 patients 0.271425 total abdominal hysterectomy 0.337207 primary treatment 0.256866 treatment clinical trial 0.254498 NCI PDQ cancer 0.256529 Treatment Option Overview 0.259623 surgical procedure 0.271995 radiation therapy 0.310569 Treatment Editorial Board 0.252931 General information 0.260406 Serum tumor marker 0.253975	general cancer information 0.252204 treatment 0.470981 ovarian germ cell 0.990461 abdomen 0.27139 Peritoneal Cancer Treatment 0.272441 NCI-supported cancer 0.272026 cancer cells 0.336912 Cancer Information Service 0.252497 treatment clinical trials 0.274003 National Cancer Institute 0.311767 Primary Peritoneal Cancer 0.275614 tumor cells 0.338991 new treatment 0.324139 diagnose ovarian germ 0.30268 combination chemotherapy 0.271369 primary tumor 0.253062 metastatic tumor 0.262931 germ cell tumors 0.577174 common ovarian germ 0.287657 cancer clinical trials 0.319376 stage 0.300535 fallopian tubes 0.264303 cancer 0.662842 information 0.326655	CLICK HERE
1698	National Cancer Institute	Html	en	Topics in Integrative, Alternative, and Complementary Therapies (PDQ®)–Patient Version	Expert-reviewed information summary that contains information on integrative, complementary, and/or alternative therapies for people with cancer.	treatment 0.496567 cancer treatment 0.492995 cancer prevention 0.491725 Complementary Therapies Editorial 0.451339 Cancer Information Specialist 0.463468 cancer cells 0.485902 section 0.463945 Cancer Information Service 0.487907 Herbs/Dietary Supplements section 0.454711 Cancer Complementary 0.464741 breast cancer section 0.455211 CAM therapies 0.453618 specific PDQ summary 0.507776 dietary supplements 0.518422 National Cancer Institute 0.533776 studies 0.454937 clinical trials 0.547318 cancer information summary 0.522295 alternative medicine 0.513784 PDQ documents 0.462433 alternative cancer therapies 0.45948 clinical trial 0.455001 prostate cancer cells 0.455068 CAM cancer research 0.449455	PDQ health 0.555354 PDQ summaries 0.468855 cancer patients 0.523763 PDQ database 0.46397 PDQ Topics 0.462207 fight cancer 0.449901 breast cancer 0.455561 prostate cancer patients 0.471774 NCI’s PDQ 0.468435 PDQ summary 0.513781 professional summary 0.498282 body fight cancer 0.448775 NCI PDQ cancer 0.502954 cancer information database 0.46436 prostate cancer 0.542459 complementary therapies 0.470524 alternative therapies 0.455648 hot flashes 0.501425 cancer information summaries 0.489288 cancer 0.694704 information 0.593851 PDQ Integrative 0.464074 PDQ patient summary 0.974252	CLICK HERE
1973	National Cancer Institute	Html	es	Tratamiento del cáncer de glándulas salivales (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del cáncer de glándulas salivales.	Neck Cancer 0.247421 siguientes procedimientos 0.717657 siguientes aspectos 0.315855 estadio ii 0.901856 vía oral 0.251714 rayos x 0.574567 pequeñas marcas 0.24571 enlace drugs approved 0.287895 exploración tac 0.270837 National Cancer Institute 0.238285 siguientes riesgos 0.235555 Instituto Nacional 0.352284 malla ayuda 0.248945	PDQ Tratamiento 0.283565 partículas minúsculas 0.2536 radioterapia envía neutrones 0.431263 presente sección 0.245937 explorador tep 0.281651 Physician Data Query 0.352077 estadio iii 0.736431 principales cánceres 0.411638 siguientes situaciones 0.301582 ganglio linfático mide 0.91402 cáncer.ampliar radioterapia 0.391316 siguientes enlaces 0.247009 siguientes pruebas 0.31121	CLICK HERE
2070	National Cancer Institute	Html	es	Inhibidores de la angiogénesis	Hoja informativa que describe el proceso de eliminación de suministro de sangre a los tumores. Incluye una lista de los cánceres en los que se está probando este enfoque.	vasos sanguíneos resultantes 0.32417 NCI de estudios 0.304711 llamadas metástasis 0.305878 posibles efectos 0.304824 Drug Administration 0.306756	células renales 0.307581 angiogénesis efectos 0.326284 Estados Unidos 0.315596 vasos sanguíneos 0.986577	CLICK HERE
3568	National Cancer Institute	Html	en	An Overview of NCI’s National Clinical Trials Network	Information about the National Clinical Trial Network’s structure and a synopsis of how NCTN improves the speed and efficiency of cancer clinical trials.	clinical trials experts 0.464501 future clinical trials 0.469163 University Comprehensive Cancer 0.556492 new clinical trials 0.515991 University Cancer Center 0.54987 lung cancer 0.503721 Colorado Cancer Center 0.501413 National Clinical Trials 0.541018 Siteman Cancer Center 0.555425 clinical trials 0.992586 Laboratory Cancer Center 0.490529 Cancer Center 0.943642 University Medical Center 0.534585 Stephenson Cancer Center 0.498802 Michigan Comprehensive Cancer 0.464216 Collaborating Clinical Trials 0.493315 NCI Community Cancer 0.50292 precision medicine 0.594538 Canadian Network Group 0.472202 multi-site clinical trials 0.481274 NCTN group 0.467958 precision medicine trials 0.572352 Cancer Research Center 0.514033 Case Comprehensive Cancer 0.469578 NCTN trials 0.551195	network groups 0.486781 Lineberger Comprehensive Cancer 0.520793 NCI clinical trials 0.553596 Anderson Cancer Center 0.500046 Clinical Trials Quality 0.474372 Clinical Trials Network 0.579967 Farber/Harvard Cancer Center 0.50471 Carbone Cancer Center 0.498624 Davis Comprehensive Cancer 0.464747 Simmons Cancer Center 0.49746 Winship Cancer Institute 0.520221 new national clinical 0.508498 Cooperative Group program 0.540619 Yale Cancer Center 0.49495 Ohio State University 0.480826 Comprehensive Cancer Center 0.860218 Kimmel Comprehensive Cancer 0.464896 Chicago Comprehensive Cancer 0.464567 previous clinical trials 0.494398 Cancer Institute 0.668695 cancer clinical trials 0.605684 cell lung cancer 0.474785 Cotton Cancer Center 0.50297 Ingram Cancer Center 0.497253	CLICK HERE
3652	National Cancer Institute	Html	es	Cannabis y canabinoides (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos sobre el uso del Cannabis y canabinoides para el tratamiento de los efectos secundarios relacionados con el tratamiento del cáncer, como la náusea y el vómito.	Natl Acad Sci 0.394203 cannabinoid receptor cb2 0.362796 Neck Cancer Epidemiology 0.340717 with peripheral cb1 0.353749 accessed october 0.451422 receptores cb2 0.414613 Sin embargo 0.375752 receptores cb1 0.617059 Mol Cancer Ther 0.460254 cb2 receptors 0.369543 marijuana as 0.341164 potencial receptor 0.334026 cannabinoid cb1 0.353877 Nat Rev Cancer 0.38837 receptor cb2 0.381409 receptor cb1 0.494644 endogenous cannabinoid 0.347836 Cancer Res 0.471447 Pharmacol Biochem Behav 0.366013 Marihuana Tax Act 0.373003 cannabinoid receptor activation 0.352792 lesiones premalignas 0.350108 cannabinoid receptor with 0.35689 Estados Unidos 0.902915 endogenous cannabinoid system 0.33287	Pain Symptom Manage 0.358772 endocannabinoid system as 0.404957 Integrating cannabis 0.433732 Pharmacol Rev 0.370877 Targeting CB2 cannabinoid 0.338858 ancient cannabis from 0.417929 Cannabidiol inhibits 0.365208 Proc Natl Acad 0.396634 canabinoides endógenos 0.435834 cannabinoid receptor 0.890303 CB2 receptor agonists 0.350942 cannabis sativa l 0.444025 Blázquez C 0.343327 chemokine receptor cxcr4 0.338077 Cannabis sativa extract 0.416057 cell proliferation 0.33314 sistema nervioso central 0.343143 breast cancer 0.515229 Cannabis medicinal 0.719247 receptores canabinoides 0.400314 emerging target 0.333482 Cannabis versus 0.409865 agonistas canabinoides 0.344588 CB2 cannabinoid 0.361915	CLICK HERE
16680	National Cancer Institute	Html	en	Cancer Moonshot℠ Implementation	Implementation teams are considering multiple ways to fund new programs as well as expansions of ongoing efforts to advance the goals of the Cancer Moonshot.	Cancer Moonshot-related research 0.688251 ongoing efforts 0.579887 funding opportunity announcements 0.69197 authorization 0.517804 oversight 0.515337 Cancer Moonshot portfolio 0.716496 academia 0.515431 Cancer Moonshot goals 0.684682 Century Cures Act 0.85793 expansions 0.51624 implementation teams 0.716347 email Partnerships_CancerMoonshot 0.582993 list 0.516345 Scientific Advisors 0.584259 important role 0.585193 longer-term scientific initiatives 0.700429 research opportunities 0.75591 multiple ways 0.591922 private sector 0.587499 Cancer Moonshot 0.987984 Cancer Moonshot initiatives 0.68956 concept proposals 0.656557 automatic email 0.583279 receipt 0.519207	NCI intramural staff 0.745934 cancer research community 0.682183 NCI extramural program 0.749793 Program Leadership Committee 0.655079 potential partners 0.586537 available FOAs 0.62206 NCI’s Board 0.674346 NIH institutes 0.582819 existing funds 0.59672 new research opportunities 0.683581 21st Century Cures 0.861565 scientific opportunities 0.594628 Blue Ribbon Panel 0.846596 BRP recommendation 0.740701 working groups 0.588634 new funding concepts 0.653803 BRP recommendations 0.654047 Public-private partnerships 0.590589 Cancer Moonshot implementation 0.678145 NCI advisory committees 0.753041 NCI’s Scientific 0.67691 report 0.517155 new programs 0.586358 funding mechanism 0.587953	CLICK HERE
16708	National Cancer Institute	Html	en	ALCHEMIST (The Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials): Questions and Answers	ALCHEMIST represents three integrated, precision medicine trials that are designed to identify people with early-stage lung cancer who have tumors that harbor certain uncommon genetic changes and evaluate whether drug treatments targeted against those mol	certain genetic alterations 0.511031 ALK gene rearrangement 0.86792 specific genetic alterations 0.510493 lung cancer 0.965003 ALK genetic alterations 0.561732 component trials 0.510228 National Clinical Trials 0.497396 clinical trials 0.62346 early-stage lung cancer 0.707269 EGFR gene mutation 0.628828 best treatment approach 0.483241 lung cancers 0.649896 ALK Treatment component 0.564764 ECOG-ACRIN Cancer Research 0.536673 ALK rearrangement 0.515701 non-small cell lung 0.519586 Adjuvant Lung Cancer 0.554841 EGFR gene mutations 0.510846 uncommon genetic changes 0.484048 ALCHEMIST treatment trial 0.613717 new treatment approaches 0.481108 lung carcinoid tumors 0.539366 early-stage lung cancers 0.57159 appropriate ALCHEMIST treatment 0.663904	ALK gene 0.888431 precision medicine trials 0.560161 tumor tissue 0.58358 United States 0.513049 Dana-Farber Cancer Institute 0.495276 ALK alterations 0.531283 small cell lung 0.519071 National Cancer Institute 0.484824 ALCHEMIST study 0.594796 cancer risk characteristics 0.487226 EGFR Treatment component 0.512344 participants 0.568322 ALCHEMIST treatment trials 0.868218 genetic alterations 0.637424 complete surgical removal 0.527484 Cancer Research Group 0.536403 early-stage lung adenocarcinoma 0.54246 cell lung cancer 0.575738 Cancer Genomics 0.482098 FDA-approved Vysis ALK 0.52631 ALCHEMIST screening trial 0.716569 ALCHEMIST trials 0.680442 standard therapy 0.505511 Clinical Trials Agreement 0.491455	CLICK HERE